GAITHERSBURG, Md., Jan. 29, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced the closing of its previously announced registered direct offering pursuant to a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The gross proceeds to the Company were approximately $75 million, before deducting placement agent fees and other offering expenses. All of the shares and pre-funded warrants in the offering are being offered by Altimmune. The pre-funded warrants have an exercise price of $0.001 per share, are exercisable immediately upon issuance and will not expire until fully exercised.

GAITHERSBURG, Md., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Altimmune, Inc. (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing pemvidutide to address serious liver diseases, announced today that it has entered into a securities purchase agreement with a new fundamental institutional investor for the purchase and sale of 17,045,454 shares of its common stock (or pre-funded warrants in lieu thereof) pursuant to a registered direct offering. The offering is expected to result in gross proceeds of approximately $75 million, before deducting placement agent fees and other offering expenses. All of the shares and pre-funded warrants in the offering are being offered by Altimmune. The offering is expected to close on or about January 29, 2026, subject to the satisfaction of customary closing conditions.

Shares of Altimmune ( NASDAQ:ALT ) surged 35.4% over the past week, coinciding with a dramatic shift in retail investor sentiment on Reddit.

LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (NASDAQ: ALTS) (the “Company”), a fintech company that maintains a strategic $WLFI digital asset treasury and provides blockchain-powered payment and trading infrastructure for digital assets, including card-based payment programs, today announced its financial results for the fiscal quarter ended September 27, 2025. The results include significant financial strategic and operational milestones from the quarter, including meaningful progress to.

Altimmune shares rally 16.52% after the FDA grants Breakthrough Therapy status to pemvidutide for MASH.

Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA Alignment on Phase 3 registrational trial parameters confirmed following receipt of minutes from end-of-phase 2 meeting with U.S. FDA

LAS VEGAS--(BUSINESS WIRE)--ALT5 Sigma Corporation (the “Company” or “ALT5”) (NASDAQ: ALTS)(FRA: 5AR1), a fintech company operating institutional-grade global payments, trading, and settlement infrastructure, today congratulated its strategic partner World Liberty Financial (“WLFI”) on its USD1 stablecoin surpassing $3 billion in market capitalization. “We are thrilled to publicly celebrate World Liberty Financial on this tremendous milestone,” said Tony Isaac, CEO of ALT5. “John F. Kennedy pop.

Beaten-down biotech stocks like ALT, IBRX and MCRB are eyeing a 2026 rebound as FDA alignment, pipeline progress and approvals fuel optimism.

San Diego, California--(Newsfile Corp. - December 24, 2025) - The law firm of Robbins Geller Rudman & Dowd LLP is investigating potential violations of U.S. federal securities laws involving ALT5 Sigma Corporation (NASDAQ: ALTS) focused on whether ALT5 Sigma and certain of its top executives made false and/or misleading statements and/or failed to disclose material information to investors. If you have information that could assist in the ALT5 Sigma investigation or if you are an ALT5 Sigma investor who suffered a loss and would like to learn more, you can provide your information here: https://www.rgrdlaw.com/cases-alt5-sigma-corporation-investigation-alts.html You can also contact attorneys J.C.

Altimmune delivered strong 48-week Phase IIb data for pemvidutide in MASH, supporting progression to Phase III. Pemvidutide showed durable, dose-dependent improvements in non-invasive fibrosis markers and consistent safety, with weight loss reaching 7.5% at 1.8 mg. Regulatory alignment for a Phase III trial targeting accelerated approval appears promising, with biopsy-based endpoints and a planned 2.4 mg dose.